Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech Investment on the Rise (Taiwan)

This article was originally published in PharmAsia News

Executive Summary

Taiwan is well on its way to becoming one of the leading biotechnology centers in Asia. International biotechnology firm MediVas LLC has selected Taiwan as the launch point for its entry into the region. MediVas chose Taiwan over competitors like China and India because of strong government backing for the further growth of the biotech and pharmaceutical markets. For example, Taiwan's National Development Fund has recently announced a $20 million investment in TaiMed Biologic's Co., a biotechnology company that recently acquired a patent for a promising new AIDS treatment. For its part, MediVas focuses on improving drug-delivery. Its Taiwan facility is expected to concentrate on using superior delivery methods to create "super-generic" pharmaceuticals. Super-generics are expired-patent drugs that would be re-patented by MediVas using more effective forms of delivery than the original treatment. (Click here for more

You may also be interested in...



FDA Approves Medtronic’s Abre Venous Stent

The approval is based on the results ABRE clinical study, which showed the stent improved patency iliofemoral veins in 88% of cases with a 2% rate of major adverse events.

AbbVie Investors Look For Stabilizing Botox Revenues In Q3 Financials

Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.

COVID-19 Could Drive UK OTC Rises

Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.

UsernamePublicRestriction

Register

LL1127674

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel